Interv Akut Kardiol. 2020;19(2):97-100 | DOI: 10.36290/kar.2020.025

Importance of modern antidiabetic drugs for the cardiologist and diabetologist

Alena ©mahelová
III. interní gerontometabolická klinika FN a LF UK Hradec Králové

SGLT2 inhibitors - gliflozins - are a novel group of antidiabetic drugs whose action is independent of insulin secretion from pancreatic beta cells. In addition to affecting hyperglycaemia without a risk of hypoglycaemia, they contribute to reducing weight and hypertension. Large randomized clinical trials of these antidiabetic drugs have not only confirmed their cardiorenal safety, but also have shown other major benefits. In type 2 diabetic patients who more often present with cardiorenal syndrome, atherosclerotic cardiovascular disease, renal involvement, and increased risk of heart failure (also seen in non-diabetics), these drugs have a protective effect. Currently, their importance is appreciated not only in secondary, but also in primary prevention of cardiorenal involvement, and, along with GLP-1 analogues, they are recommended as drugs suitable for intensification of antidiabetic therapy second only to metformin and as the only possible oral antidiabetic agent for intensive insulin therapy of type 1 diabetes.

Keywords: type 2 diabetes, type 1 diabetes, cardiorenal syndrome, cardiovascular complications, chronic kidney disease, prevention, gliflozins.

Published: June 2, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
©mahelová A. Importance of modern antidiabetic drugs for the cardiologist and diabetologist. Interv Akut Kardiol. 2020;19(2):97-100. doi: 10.36290/kar.2020.025.
Download citation

References

  1. Einarson TR, et al. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017. 018; 17: 83-102. Go to original source... Go to PubMed...
  2. Ronco C, et al. Cardiorenal syndrome. J Am Coll Cardiol 2008; 52: 1527-1539. Go to original source... Go to PubMed...
  3. Dalrymple L, et al. Chronic Kidney Disease and the Risk of End-Stage Renal Disease versus Death. J Gen Intern Med 2011; 26: 379-385. Go to original source... Go to PubMed...
  4. Raz I, et al. DECLARE‑TIMI 58: Participants' baseline characteristics. Diabetes Obes Metab 2018; 20: 1102-1120. Go to original source... Go to PubMed...
  5. Zelniker TA, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 2019; 393: 31-9. Go to original source...
  6. Wanner C, Inzucchi SC, Lachin JM, et al. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. NEJM, 2016; 375: 323-334. Go to original source...
  7. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med 2017; 377: 644-657. Go to original source...
  8. Meg J. Jardine MJ, Kenneth MW, et al. The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics. Am J Nephrol 2017; 46: 462-472. Go to original source...
  9. Murray J, Solomon S. Izucchi S, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med 2019; 381: 1995-2008. Go to original source...
  10. Martinez FA, et al. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF. Circulation 2020; 141(2): 100-111. Go to original source...
  11. Davies MJ, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2018; 61(12): 2461-2498.
  12. American Diabetes Association. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes 2020. Diabetes Care 2020; 43(Suppl. 1): S98-S110. Go to original source...
  13. Buse JB, et al. 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2020; 63(2): 221-228.
  14. Lalau JD. Metformin Treatment in Patients With Type 2 Diabetes and Chronic Kidney Disease Stages 3A, 3B, or 4. Diabetes Care. 2018; 41(3): 547-553. Go to original source...
  15. Charytan DM. Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2019; 21(5): 1199-1208. Go to original source...
  16. Chiang CE, et al. Second Revolution in Cardiovascular Prevention. J Chin Med Assoc. 2020: Epublikace. Go to original source... Go to PubMed...
  17. Bhatt D, et al. The DAPA-HF Trial: A Momentous Victory in the War against Heart Failure. Cell Metab. 2019; 30(5): 847-884. Go to original source...




Interventional Cardiology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.